You just read:

Polaryx Therapeutics Receives IND Approval From the FDA to Study PLX-200 Treatment for Patients With Juvenile Neuronal Ceroid Lipofuscinosis

News provided by

Polaryx Therapeutics, Inc

Apr 08, 2020, 00:00 ET